Heron Therapeutics Inc vs J B Hunt Transport Services Inc — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while J B Hunt Transport Services Inc trades at $292.07 (market cap $27.36B). The key difference: J B Hunt Transport Services Inc is far larger — about 299.1× Heron Therapeutics Inc's market cap, and J B Hunt Transport Services Inc pays a 0.62% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | JBHT | |
|---|---|---|
Market Cap | $91.46M | $27.36B |
Sector | Health | Industrials |
52-Week High | $1.96 | $298.41 |
52-Week Low | $0.39 | $130.65 |
Enterprise Value | $189.36M | $28.50B |
Dividend Yield | — | 0.62% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
JBHT trades at $290.43, down 0.34% today but near its 52-week high, with a bullish technical outlook and consistent earnings beats. The stock shows strong momentum, supported by intermodal growth and cost discipline. Recent Q2 2026 EPS of $1.91 beat estimates by 12%, driving positive sentiment. Valuation remains elevated with a P/E of 41.45, reflecting high growth expectations amid industry capacity constraints.
Outlook is positive due to structural freight market shifts and operational efficiency, but risks include premium valuation sensitivity and economic cyclicality. Analyst consensus favors Buy with a $299.82 target, suggesting modest upside. Investors should weigh robust fundamentals against potential margin pressures from rising costs.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →